Vitreomacular Traction Treatment JETREA(R) Gains EU Approval

on

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that the European Commission has approved JETREA(R) (ocriplasmin) in the European Union…